Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

571 results about "PTK Inhibitors" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

A protein kinase inhibitor is a type of enzyme inhibitor that blocks the action of one or more protein kinases. Protein kinases are enzymes that add a phosphate (PO4) group to a protein, and can modulate its function.

AKT protein kinase inhibitors

InactiveUS20050130954A1BiocideOrganic chemistryPTK InhibitorsEnantiomer

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

AKT protein kinase inhibitors

AKT protein kinase inhibitors

AKT protein kinase inhibitors

Owner:ARRAY BIOPHARMA

6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors

ActiveUS20060235031A1Treatment and/or prevention of hyperproliferative diseasesBiocideSenses disorderDiseasePTK Inhibitors

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and / or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy / asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors

6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors

6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors

Owner:ACERTA PHARMA BV

Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors

InactiveUS7098330B2BiocideNervous disorderArylPTK Inhibitors

This invention describes novel pyrazole compounds of formula III:wherein Ring D is a 5–7 membered monocyclic ring or 8–10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5–8 membered carbocyclo ring; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors

Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors

Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors

Owner:VERTEX PHARMA INC

Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors

InactiveUS7008948B2BiocideNervous disorderArylPTK Inhibitors

This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors

Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors

Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors

Owner:VERTEX PHARMA INC

Pyrazole compounds useful as protein kinase inhibitors

InactiveUS6989385B2BiocideSenses disorderArylPTK Inhibitors

This invention describes novel pyrazole compounds of formula IIc: wherein R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 heteroatoms; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Pyrazole compounds useful as protein kinase inhibitors

Pyrazole compounds useful as protein kinase inhibitors

Pyrazole compounds useful as protein kinase inhibitors

Owner:VERTEX PHARMA INC

Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors

InactiveUS20100048540A1Impart oxidative damage to surrounding DNAInhibitory activityBiocideOrganic chemistryPTK InhibitorsBiochemistry

The invention relates to novel heterocyclic N-oxides which are useful as hypoxic selective cytotoxic agents that mediate and / or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further related to pharmaceutical compositions containing such compounds and compositions, and to methods of treating cancer as well as other disease states associated with unwanted ahgiogenesis and / or cellular proliferation by administering effective amounts of such compounds.

Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors

Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors

Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors

Owner:SENTINEL ONCOLOGY

Pyrazolopyrimidines as protein kinase inhibitors

InactiveUS20060094706A1Reduce usageUseful in treatmentBiocideSteroidsDiseasePTK Inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and / or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. The invention also relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

Pyrazolopyrimidines as protein kinase inhibitors

Pyrazolopyrimidines as protein kinase inhibitors

Pyrazolopyrimidines as protein kinase inhibitors

Owner:MERCK SHARP & DOHME LLC

Compositions useful as inhibitors of protein kinases

InactiveUS6846928B2Avoid cell deathTreat and prevent reperfusion/ischemiaBiocideOrganic chemistryDiseasePTK Inhibitors

The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Compositions useful as inhibitors of protein kinases

Compositions useful as inhibitors of protein kinases

Compositions useful as inhibitors of protein kinases

Owner:VERTEX PHARMA INC

Protein Kinase Inhibitors

InactiveUS20090143399A1Inhibits protein kinase activityOrganic active ingredientsOrganic chemistryDiseasePTK Inhibitors

Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from:and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Protein Kinase Inhibitors

Protein Kinase Inhibitors

Protein Kinase Inhibitors

Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA +1

Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors

ActiveUS7750007B2Inhibitory activityBiocideOrganic chemistryProtein kinase inhibitor activityPTK Inhibitors

The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II):or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.

Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors

Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors

Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors

Owner:SUMITOMO PHARMA ONCOLOGY INC

4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors

InactiveUS6610688B2BiocideOrganic active ingredientsDiseasePTK Inhibitors

This invention relates to 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors. Particular 4-substituted 7-aza-indolin-2-ones disclosed herein are of Formula 1and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, X, Y, and Z are defined herein. The invention further relates to pharmaceutical compositions and dosage forms comprising compounds of Formula 1 and to methods of their use for the treatment and / or prevention of diseases such as, but not limited to, cancer.

4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors

4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors

4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors

Owner:SUGEN INC

Indazole compounds useful as protein kinase inhibitors

InactiveUS7041687B2Reduce severityBiocideNervous disorderPTK InhibitorsTyrosine-kinase inhibitor

The present invention provides compounds of formula I:or a pharmaceutically acceptable derivative thereof, wherein R1, R2, V1, V2, and V3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.

Indazole compounds useful as protein kinase inhibitors

Indazole compounds useful as protein kinase inhibitors

Indazole compounds useful as protein kinase inhibitors

Owner:VERTEX PHARMA INC

Heterocyclic inhibitors of ERK2 and uses thereof

InactiveUS7253187B2Antibacterial agentsBiocideDiabetes mellitusPTK Inhibitors

Described herein are compounds that are useful as protein kinase inhibitors having the formula:wherein Z1 and Z2 are each independently nitrogen or CH and Ring A, TmR1, QR2, UnR3, and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

Heterocyclic inhibitors of ERK2 and uses thereof

Heterocyclic inhibitors of ERK2 and uses thereof

Heterocyclic inhibitors of ERK2 and uses thereof

Owner:VERTEX PHARMA INC

Heterocyclic inhibitors of ERK2 and uses thereof

InactiveUS20050234059A1BiocideOrganic chemistryPTK InhibitorsMedicine

Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

Heterocyclic inhibitors of ERK2 and uses thereof

Heterocyclic inhibitors of ERK2 and uses thereof

Heterocyclic inhibitors of ERK2 and uses thereof

Owner:VERTEX PHARMA INC

Pyrazole compounds useful as protein kinase inhibitors

InactiveUS7691853B2Organic active ingredientsBiocideDiseasePTK Inhibitors

This invention describes novel pyrazole compounds of formula IV:wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T—R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Pyrazole compounds useful as protein kinase inhibitors

Pyrazole compounds useful as protein kinase inhibitors

Pyrazole compounds useful as protein kinase inhibitors

Owner:VERTEX PHARMA INC

Pyrazole compounds useful as protein kinase inhibitors

InactiveUS20050004110A1BiocideNervous disorderDiseaseAryl

This invention describes novel pyrazole compounds of formula III: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered carbocyclo ring; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Pyrazole compounds useful as protein kinase inhibitors

Pyrazole compounds useful as protein kinase inhibitors

Pyrazole compounds useful as protein kinase inhibitors

Owner:VERTEX PHARMA INC

Protein kinase inhibitors

InactiveUS20050227992A1Organic active ingredientsOrganic chemistryDiseasePTK Inhibitors

Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Protein kinase inhibitors

Protein kinase inhibitors

Protein kinase inhibitors

Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors

ActiveUS20100004239A1BiocideSenses disorderPTK InhibitorsTyrosine-kinase inhibitor

The present invention relates to pyrrolo[3,2-c]pyridine-4-one 2-indolinone compounds of Formula (I) and their pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8X, Y and have the meaning cited in the specification. Also disclosed are the pharmaceutical compositions containing the foregoing compounds, methods for the preparation and pharmaceutical use thereof, particularly as protein kinase inhibitors. Formula (I).

Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors

Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors

Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors

Owner:SHANGHAI HENGRUI PHARM CO LTD

Heterocyclic inhibitors of ERK2 and uses thereof

InactiveUS7304061B2BiocideOrganic chemistryPTK InhibitorsMedicine

Described herein are compounds that are useful as protein kinase inhibitors having the formula:wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

Heterocyclic inhibitors of ERK2 and uses thereof

Heterocyclic inhibitors of ERK2 and uses thereof

Heterocyclic inhibitors of ERK2 and uses thereof

Owner:VERTEX PHARMA INC

Pyrazole compositions useful as inhibitors of ERK

InactiveUS6949580B2BiocideNervous disorderPTK InhibitorsMammal

Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1, R2, T and Ht are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

Pyrazole compositions useful as inhibitors of ERK

Pyrazole compositions useful as inhibitors of ERK

Pyrazole compositions useful as inhibitors of ERK

Owner:VERTEX PHARMA INC

Imidazopyrazines as protein kinase inhibitors

InactiveUS20070117804A1BiocideSenses disorderProteinPTK Inhibitors

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and / or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

Imidazopyrazines as protein kinase inhibitors

Imidazopyrazines as protein kinase inhibitors

Imidazopyrazines as protein kinase inhibitors

Owner:SCHERING CORP

Bicyclic protein kinase inhibitors

InactiveUS20070149521A1BiocideOrganic chemistryPTK InhibitorsDisease cause

Compounds of the Formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit protein kinase enzymes and are useful for the treatment and / or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy / asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Bicyclic protein kinase inhibitors

Bicyclic protein kinase inhibitors

Bicyclic protein kinase inhibitors

Owner:OSI PHARMA INC

Pyrazole compositions useful as inhibitors of erk

InactiveUS7056944B2BiocideNervous disorderPTK InhibitorsMammal

Described herein are compounds that are useful as protein kinase inhibitors having the formula:where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

Pyrazole compositions useful as inhibitors of erk

Pyrazole compositions useful as inhibitors of erk

Pyrazole compositions useful as inhibitors of erk

Owner:VERTEX PHARMA INC

Heterocyclic inhibitors of ERK2 and uses thereof

InactiveUS7345054B2BiocideOrganic chemistryPTK InhibitorsCardio vascular disease

Described herein are compounds that are useful as protein kinase inhibitors having the formula:wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

Heterocyclic inhibitors of ERK2 and uses thereof

Heterocyclic inhibitors of ERK2 and uses thereof

Heterocyclic inhibitors of ERK2 and uses thereof

Owner:VERTEX PHARMA INC

Pyrazolopyrimidines as protein kinase inhibitors

ActiveUS20070082902A1Organic active ingredientsBiocidePTK InhibitorsPharmaceutical formulation

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and / or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

Pyrazolopyrimidines as protein kinase inhibitors

Pyrazolopyrimidines as protein kinase inhibitors

Pyrazolopyrimidines as protein kinase inhibitors

Owner:MERCK SHARP & DOHME LLC

Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors

InactiveUS7772231B2BiocideOrganic chemistryDiseasePTK Inhibitors

Compounds of formula (25) that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors

Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors

Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors

Owner:ABBVIE INC

Phthalimide compounds useful as protein kinase inhibitors

InactiveUS20050182061A1BiocideOrganic chemistryPTK InhibitorsNeuro-degenerative disease

The present invention provides compounds as inhibitors of protein kinase, particularly inhibitors of AKT, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides processes for preparing the compounds of the invention, pharmaceutical compositions comprising the compounds, and methods of utilizing those compounds and compositions in the treatment of various disorders.

Phthalimide compounds useful as protein kinase inhibitors

Phthalimide compounds useful as protein kinase inhibitors

Phthalimide compounds useful as protein kinase inhibitors

Owner:GREEN JEREMY +1

Protein Kinase Inhibitors

InactiveUS20080051414A1Inhibits protein kinase activityOrganic active ingredientsOrganic chemistryDiseasePTK Inhibitors

Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Protein Kinase Inhibitors

Protein Kinase Inhibitors

Protein Kinase Inhibitors

Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA +1

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

InactiveUS20120277424A1Improve abilitiesPreventing and treating diseaseOrganic active ingredientsBiocideDiseasePTK Inhibitors

Disclosed are a 2,7-substituted thieno[3,2-d]pyrimidine compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of diseases caused by abnormal cell growth comprising the compound as an effective ingredient.

Since the novel 2,7-substituted thieno[3,2-d]pyrimidine compound exhibits superior inhibition activity against various protein kinases involved in growth factor signal transduction, it is useful as an agent for preventing or treating diseases caused by abnormal cell growth.

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

2,7-substituted thieno[3,2-d] pyrimidine compounds as protein kinase inhibitors

Owner:KOREA INST OF SCI & TECH

Imidazotriazines as protein kinase inhibitors

InactiveUS20060019957A1Treatment and/or preventionAntibacterial agentsBiocideDiseasePTK Inhibitors

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and / or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.

Imidazotriazines as protein kinase inhibitors

Imidazotriazines as protein kinase inhibitors

Imidazotriazines as protein kinase inhibitors

Owner:OSI PHARMA INC

Popular searches

Compound (substance) Diastereomer Kinase protein Disease injury Protein kinase inhibitor Cancer Allergy Pharmaceutical medicine Nervous disease Kinase inhibition

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Eureka Blog

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com